-transparent.png){kind=logo}
During the last 10 years, several cases of myocardial infarction associated with anabolic steroid use have been reported. Postulated mechanisms to explain this association have included changes in lipid levels, the fibrinolytic system, and platelet aggregation. Clenbuterol is a beta 2-agonist with anabolic properties that has not been seen previously with myocardial infarction. We report a case of myocardial infarction in an otherwise healthy 26-year-old body-builder who recently used clenbuterol and anabolic steroids. In this case, synergistic effects of the two agents seem likely to have played a role in the infarct. The normal coronary arteriograms before any anticoagulant or thrombolytic therapy strongly suggest coronary spasm as the mechanism of the infarct.
D R Goldstein, and
T Dobbs, and
B Krull, and
V J Plumb
January 1970,
American heart journal,
D R Goldstein, and
T Dobbs, and
B Krull, and
V J Plumb
December 1971,
The American journal of cardiology,
D R Goldstein, and
T Dobbs, and
B Krull, and
V J Plumb
October 1971,
Circulation,
D R Goldstein, and
T Dobbs, and
B Krull, and
V J Plumb
July 1975,
The Western journal of medicine,
D R Goldstein, and
T Dobbs, and
B Krull, and
V J Plumb
June 1976,
The American journal of cardiology,
D R Goldstein, and
T Dobbs, and
B Krull, and
V J Plumb
June 1976,
The American journal of cardiology,
D R Goldstein, and
T Dobbs, and
B Krull, and
V J Plumb
January 1977,
Catheterization and cardiovascular diagnosis,
D R Goldstein, and
T Dobbs, and
B Krull, and
V J Plumb
September 1974,
Annals of internal medicine,
D R Goldstein, and
T Dobbs, and
B Krull, and
V J Plumb
April 1980,
American heart journal,
D R Goldstein, and
T Dobbs, and
B Krull, and
V J Plumb
August 1995,
Medicine and science in sports and exercise,
